Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerodalcibep in CVD patients on stable lipid-lowering therapy
NCT04797247Phase 3Active, not recruiting
- Sponsor
- LIB Therapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of lerodalcibep in hypercholesterolemia, cardiovascular diseases (CVD), sponsored by LIB Therapeutics. Started Apr 2021; status: active, not recruiting.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiacardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04797247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797247.